Clinical Trial Update: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated the mTOR inhibitor everolimus (RAD001) for angiomyolipomata in patients with tuberous sclerosis complex and sporadic lymphangioleiom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphangioleiomyomatosis
• Tuberous Sclerosis Complex

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 1, Phase 2 | Status: COMPLETED